Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Physical Activity Reduces Prostate Carcinogenesis In A Transgenic Model
UroToday.com - A recent European study demonstrated that 10-year mortality from cardiovascular disease and cancer was decreased in a population of 70 to 90 year olds who adhered to a Mediterranean diet, were physically active, had moderate alcohol consumption and did not smoke. There are also reports suggesting an inverse association between physical activity and risk of prostate cancer (CaP). Yet mechanisms linking lifestyle and longevity are not well investigated. This report in The Prostate investigates an animal model for the association between physical activity and development of CaP.
generic viagra online
Building A Better Blend Of Tumor-Fighting Cells
Israeli researchers have developed a technique that could produce a more effective blend of tumor-fighting immune cells used to treat cancers such as metastatic melanoma.
News of the day
What Is Endocarditis? Why Healthy Teeth Could Help Care For Your Heart
The word "endocarditis" comes from the word "endocardium". The endocardium is the innermost tunic of the heart, including the endothelium and subendothelial connective tissue; in the atrial wall, smooth muscle and numerous elastic fibers also occur.
Cardiovascular

Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial

Stem Cell Therapeutics Corp. ("SCT" or "the Company") (TSX VENTURE:SSS) is pleased to announce the U.S. Food and Drug Administration ("FDA") has provided a verbal confirmation to remove its clinical hold placed on NTx®-265 on September 18, 2008. This will allow SCT to commence the recruitment of patients under an amended protocol using NTx®-265 for the Company"s Phase IIb clinical trial treating acute ischemic stroke. Dr. Alan Moore, President and CEO, commented as follows: "We are very pleased that our series of collaborative meetings with the FDA has resulted in this positive development. We are expecting to receive written notification from the FDA in the near future following which we will finalize the plans for our stroke trial. We will issue another press release once this has been determined." About REGENESIS NTx®-265 is SCT"s lead therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin ("hCG") and Erythropoietin ("EPO"), targeting the treatment of stroke. The twin objectives of the treatment are to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the stroke, and importantly, to direct motor, visual, and cognitive recovery after the acute ischemic stroke. Encouraging clinical results from SCT"s BETAS Phase IIa stroke trial were presented at the International Stroke Conference in February 2009, showing clinically relevant recovery in 12 of 12 patients who received the complete treatment. Stem Cell Therapeutics Corp.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009